P53,ki-67,galectin-3,HBME-1,34βE12和CK19在甲状腺乳头状癌中的表达及临床病理意义

Expression and clinical pathology significance of P53,ki-67,galectin-3,HBME-1, 34βE12 and CK19 in papillary thyroid carcinomas

目的探讨P53,ki-67,galectin-3,HBME-1,34βE12和CK-19在甲状腺乳头状癌中的表达及临床病理意义。方法采用免疫组化检测43例甲状腺乳头状癌,37例结节性甲状腺肿,33例甲状腺腺瘤和17例桥本甲状腺炎中P53,ki-67,galectin-3,HBME-1,34βE12和CK-19的表达。结果 P53,ki-67,galectin-3,HBME-1,34βE12和CK-19在甲状腺乳头状癌中的阳性表达率分别为88.37%、79.07%、88.37%、93.02%、86.05%及95.35%,显著高于结节性甲状腺肿的18.92%、29.73%、27.03%、16.22%、24.32%和5.41%(P<0.05);也高于甲状腺腺瘤和桥本甲状腺炎中的阳性表达率(P<0.01)。结论联合检测P53,ki-67,galectin-3,HBME-1,34βE12和CK-19在诊断和鉴别诊断甲状腺乳头状癌与良性病变中具有重要的价值。

Objective To investigate the expression of P53,ki-67,galectin-3,HBME-1,34βE12 and CK-19 in the papillary thyroid carcinomas and clinical pathology significance.Methods By s-p immunohistochemical technique,the expression of P53,ki-67,galectin-3,HBME-1,34βE12 and CK-19 was detected in 43 cases of papillary thyroid carcinomas,37 multinodular goiters,33 follicular adenomas and 17 Hashimoto＇s thyroiditis.Results The expression rate of P53,ki-67,galectin-3,HBME-1,34βE12 and CK19 in the papillary thyroid carcinomas was 88.37%,79.07%,88.37%,93.02%,86.05%and 95.35% respectively.The expression rate of P53,ki-67,galectin-3,HBME-1,34βE12 and CK19 in the multinodular goiters was 18.92%,29.73%,27.03%,16.22%,24.32%和5.41% respectively.Expression of P53,ki-67,galectin-3,HBME-1,34βE12 and CK-19 were obviously different in the papillary thyroid carcinomas and benign lesions（P0.01）.Conclusion Combined application of immunohistochemical staining of P53,ki-67,galectin-3,HBME-1,34βE12 and CK-19 is a potential method to differentiate papillary thyroid carcinoma and benign lesions.